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Abstract
The recent finding that inhibitors of PI3/Akt can sensitize HIV infected macrophages to oxidative
stress-induced cell death suggest a potential new therapeutic approach to targeting HIV reservoirs.
Although antiretroviral therapy has achieved laudable
successes in combating HIV, particularly since the advent
of protease inhibitors in the mid 1990s, fully successful
treatment remains plagued by multiple, clinically latent
viral reservoirs largely impervious to antiretroviral drugs.
The microbiology of clinical latency is controversial and
may involve elements of viral quiescence (expression of
no – or a limited subset of – viral genes) as well as low
level viral replication in protected cell types or anatomical
compartments [1]. Viral persistence has been reported in
brain cells (including perivascular macrophages, paren-
chymal microglial cells and astrocytes), NK cells, renal
tubular cells, mononuclear cells from semen, follicular
dendritic cells, cells of the monocyte/macrophage lineage
(recently infected monocytes and tissue macrophages)
and resting CD4+ T cells, with the latter two being the best
known reservoirs [2-5].
Attempts at attacking the resting CD4+T cell HIV reservoir
have generally involved induction (of presumably quies-
cent virus) with IL-2, IL-7, phorbol esters, or valproic acid
[3,6,7]. Such induction approaches usually assume the
activated, HIV producing cells will be killed directly by the
induced virus or by the host immune system but some
have attempted bolstering these effects by targeting
immunotoxins to viral determinants [7]. The risk of a
spreading infection by virus newly induced to replicate is
generally mitigated in these scenarios by HAART.
Attacking the macrophage HIV reservoir has proven a
thornier issue. From the virus's standpoint macrophages
are an ideal reservoir cell because they are long lived,
because HIV does not kill macrophages by direct lysis, as
it does CD4+T cells, and because virus production by
chronically infected macrophages tends to be relatively
insensitive to a variety of antiretroviral agents [8-13].
Besides hosting a significant virus reservoir, chronically
infected macrophages and/or their brain counterparts,
microglia, may contribute to pathogenesis through
chronic aberrant release of a variety of host and viral
cytoactive factors and may be subject to chronic dysregu-
lation through aberrant expression of surface receptors
[14-20]. Thus, the recent report that PI3K/Akt inhibitors
can drastically sensitize HIV infected macrophages to oxi-
dative-stress-induced cell death [21] is welcome news as
delineating a possible novel therapeutic approach.
HIV infection in vivo increases levels of superoxide anion
and peroxynitrite, the latter of which can promote HIV
replication in macrophages[22]. Recently Chugh et al.
[23] reported that HIV infection activated the PI3K/Akt
pathway exerting a cytoprotective effect against apoptotic
challenge in a microglial cell line and in primary human
macrophages. This described a pathway by which HIV
could protect certain HIV infected cells against the oxida-
tive stress they typically endure in vivo due to the high lev-
els of nitric oxide (NO) they produce [24-27]. The finding
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that a variety of PI3K/Akt inhibitors, including wortman-
nin, Akt inhibitors IV & VIII (Calbiochem) and the clini-
cally available Miltefosine could all promote cell death in
cultures of primary human macrophages infected with
HIV, but not in uninfected controls, makes therapeutically
attacking the HIV macrophage/microglial reservoir a tan-
talizing possibility.
Recent work has contributed significantly to understand-
ing the roles of numerous HIV regulatory proteins in cells
of lineages other than the T lineage [22,28,29] and the
work highlighted here is no exception. Mechanistic stud-
ies determined that the HIV Tat can mediate the activation
of the PI3K/Akt pathway, dependent upon the Tat basic
domain (a region that binds p53 [21,23]) and that the
mediation is associated with a drop in the level of PTEN
(phosphatase tensin homolog) protein expression. SIV
Tat was also shown to mediate the cytoprotective effect (in
a microglial cell line), suggesting an evolutionarily con-
served role. The results are consistent with a model in
which Tat competes with PTEN for p53 binding, causing
p53 destabilization and a consequent reduction in PTEN
mRNA and protein levels, relieving the PTEN inhibition
of Akt activation (Figure 1).
Missing from the current in vitro findings is evidence that
endogenous production of reactive oxygen species (ROS)
in HIV infected macrophages or microglia is sufficient to
render them more susceptible than uninfected control
cells to oxidative stress-induced cell death [30,31]. Rather,
exogenous NO must be provided in vitro (in the form of
sodium nitroprusside) [21,23]. Thus, for the suggested
approach to succeed clinically, either in vivo levels of ROS
in critical local compartments must be sufficient to cause
death when the Akt pathway is inhibited – the likelihood
of which is undetermined – or such levels of ROS must be
induced – which is problematic. Time will tell.
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